Cargando…
Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most leading causes of cancer death worldwide. The 5-year survival rate of HCC patients remains low due to the lack of early-stage symptoms. Human complement factor H-related protein 4 (CFHR4) is a critical gene that belongs to the factor H fa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632743/ https://www.ncbi.nlm.nih.gov/pubmed/36338737 http://dx.doi.org/10.3389/fonc.2022.812663 |
_version_ | 1784824101761712128 |
---|---|
author | Ding, Qinglin Li, Hanluo Xu, Zhigao Hu, Kanghong Ye, Qifa |
author_facet | Ding, Qinglin Li, Hanluo Xu, Zhigao Hu, Kanghong Ye, Qifa |
author_sort | Ding, Qinglin |
collection | PubMed |
description | BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most leading causes of cancer death worldwide. The 5-year survival rate of HCC patients remains low due to the lack of early-stage symptoms. Human complement factor H-related protein 4 (CFHR4) is a critical gene that belongs to the factor H family of plasma glycoproteins, which has not been linked to HCC development. The correlations between CFHR4 and prognosis and tumor-infiltrating lymphocytes in HCC are yet unknown. The present study demonstrated the involvement of CFHR4 in HCC via data mining approaches. RESULTS: A total of 18 upregulated and 67 down-regulated differentially expressed genes (DEGs) were identified. Importantly, CFHR4, which was screened from DEGs, was shown to express at a lower level in HCC tumor tissue than normal tissues. Western blotting (WB), immunohistochemical (IHC) and quantitative reverse transcription PCR (qRT-PCR) experiments of clinical samples further validated CFHR4 was aberrantly expressed in HCC patients; Data from TCGA showed that CFHR4 was inversely correlated with a cancer family history, histological grade, tumor node metastasis (TNM) stage, and serum AFP level of HCC patients; Univariate and multivariate analyses revealed that low expression of CFHR4 was an independent predictive marker in patients with HCC; Kaplan-Meier analysis showed that the lower expression of CFHR4 was significantly associated with the progression of HCC and poor prognosis rates. Furthermore, TIMER analysis indicated that CFHR4 expression levels had correlations with infiltrating levels of immune cells in HCC. CONCLUSION: CFHR4 expression was low in HCC and was significantly related to the poor prognosis of HCC and the level of immune infiltration. CFHR4 played important roles in regulating the initiation and progression of HCC and could be a potential biomarker for the diagnosis and prognosis of HCC. METHODS: The expression of CFHR4 was analyzed by GEO and TCGA-LIHC database and verified by WB and IHC assay. The biological function of CFHR4 was performed by GO and KEGG enrichment analysis, and the genomic alteration of CFHR4 was investigated by cBioPortal database.The correlation between CFHR4 expression and clinical relevance was evaluated through Cox proportional hazards model, and the correlation between CFHR4 expression and tumor immune infiltrates were studied by TIMER database. |
format | Online Article Text |
id | pubmed-9632743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96327432022-11-04 Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma Ding, Qinglin Li, Hanluo Xu, Zhigao Hu, Kanghong Ye, Qifa Front Oncol Oncology BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most leading causes of cancer death worldwide. The 5-year survival rate of HCC patients remains low due to the lack of early-stage symptoms. Human complement factor H-related protein 4 (CFHR4) is a critical gene that belongs to the factor H family of plasma glycoproteins, which has not been linked to HCC development. The correlations between CFHR4 and prognosis and tumor-infiltrating lymphocytes in HCC are yet unknown. The present study demonstrated the involvement of CFHR4 in HCC via data mining approaches. RESULTS: A total of 18 upregulated and 67 down-regulated differentially expressed genes (DEGs) were identified. Importantly, CFHR4, which was screened from DEGs, was shown to express at a lower level in HCC tumor tissue than normal tissues. Western blotting (WB), immunohistochemical (IHC) and quantitative reverse transcription PCR (qRT-PCR) experiments of clinical samples further validated CFHR4 was aberrantly expressed in HCC patients; Data from TCGA showed that CFHR4 was inversely correlated with a cancer family history, histological grade, tumor node metastasis (TNM) stage, and serum AFP level of HCC patients; Univariate and multivariate analyses revealed that low expression of CFHR4 was an independent predictive marker in patients with HCC; Kaplan-Meier analysis showed that the lower expression of CFHR4 was significantly associated with the progression of HCC and poor prognosis rates. Furthermore, TIMER analysis indicated that CFHR4 expression levels had correlations with infiltrating levels of immune cells in HCC. CONCLUSION: CFHR4 expression was low in HCC and was significantly related to the poor prognosis of HCC and the level of immune infiltration. CFHR4 played important roles in regulating the initiation and progression of HCC and could be a potential biomarker for the diagnosis and prognosis of HCC. METHODS: The expression of CFHR4 was analyzed by GEO and TCGA-LIHC database and verified by WB and IHC assay. The biological function of CFHR4 was performed by GO and KEGG enrichment analysis, and the genomic alteration of CFHR4 was investigated by cBioPortal database.The correlation between CFHR4 expression and clinical relevance was evaluated through Cox proportional hazards model, and the correlation between CFHR4 expression and tumor immune infiltrates were studied by TIMER database. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9632743/ /pubmed/36338737 http://dx.doi.org/10.3389/fonc.2022.812663 Text en Copyright © 2022 Ding, Li, Xu, Hu and Ye https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ding, Qinglin Li, Hanluo Xu, Zhigao Hu, Kanghong Ye, Qifa Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title | Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title_full | Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title_fullStr | Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title_full_unstemmed | Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title_short | Identification of CFHR4 associated with poor prognosis of hepatocellular carcinoma |
title_sort | identification of cfhr4 associated with poor prognosis of hepatocellular carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632743/ https://www.ncbi.nlm.nih.gov/pubmed/36338737 http://dx.doi.org/10.3389/fonc.2022.812663 |
work_keys_str_mv | AT dingqinglin identificationofcfhr4associatedwithpoorprognosisofhepatocellularcarcinoma AT lihanluo identificationofcfhr4associatedwithpoorprognosisofhepatocellularcarcinoma AT xuzhigao identificationofcfhr4associatedwithpoorprognosisofhepatocellularcarcinoma AT hukanghong identificationofcfhr4associatedwithpoorprognosisofhepatocellularcarcinoma AT yeqifa identificationofcfhr4associatedwithpoorprognosisofhepatocellularcarcinoma |